This Week in Psychedelics
Feb 18, 2026
•
13 min read
[5-min read] Compass shares results from second Phase 3 psilocybin trial.
Feb 11, 2026
[5-min read] Pilot program brings at-home ketamine-assisted therapy to hospice patients.
Feb 4, 2026
12 min read
[5-min read] Preclinical research shows low-dose psilocybin reverses metabolic disease.
Jan 28, 2026
[5-min read] RAND study projects 10 million Americans microdosed in 2025.
Jan 21, 2026
[5-min read] WHO data suggests severe adverse events from psychedelics are rare.
Jan 14, 2026
[5-min read] FDA accepts Compass Pathways' application to test psilocybin for PTSD.
Jan 7, 2026
[5-min read] Real-world psilocybin therapy study tempers expectations for treatment-resistant depression.
Dec 31, 2025
10 min read
[4-min read] 2025's biggest psychedelic shifts and our predictions for 2026.
Dec 24, 2025
[5-min read] Psychedelics stocks rally after cannabis rescheduling order.
Dec 17, 2025
11 min read
[5-min read] Psilocybin reduces symptoms of OCD in 48 hours.
Dec 10, 2025
[5-min read] Researchers conduct first trial of MDMA-assisted therapy for depression.
Dec 3, 2025
[5-min read] DEA announces steep production quota increases for multiple psychedelics.
Nov 26, 2025
[5-min read] Study finds psychedelic decriminalization hasn't increased ER visits.
Nov 19, 2025
[5-min read] AtaiBeckley posts open-label extension results for its 5-MeO-DMT formulation.
Nov 12, 2025
[5-min read] Maryland task force proposes three-phased approach to psychedelic legalization.
Nov 5, 2025
[5-min read] Arizona-funded clinical trial will test whole psilocybin mushrooms for PTSD.
Oct 29, 2025
[5-min read] Ketamine company receives one of nine FDA Commissioner's National Priority Vouchers.
Oct 22, 2025
14 min read
[5-min read] atai receives FDA's seventh breakthrough therapy designation for a psychedelic drug.
Oct 15, 2025
[5-min read] Crossover trial examines the key differences between MDMA and MDA.
Oct 8, 2025
[6-min read] New research reveals how psilocybin breaks the pain-depression cycle.
Oct 1, 2025
[5-min read] Osmind shares first study of real-world outcomes from Oregon Psilocybin Services.
Sep 24, 2025
[5-min read] NIH awards atai Life Sciences $11.4 million to develop non-hallucinogenic psychedelics.
Sep 17, 2025
[5-min read] International psychedelic drugmaker files for US Initial Public Offering.
Sep 10, 2025
[5-min read] MindMed publishes full results from its Phase 2b trial of LSD for anxiety.
Sep 3, 2025
[5-min read] Brain imaging study reveals the connection between high-ventilation breathwork and mystical experiences.
